Clinical trial
An Open-label, Single Ascending Dose, Pharmacokinetic and Tolerability Study of NFC-1 in Children and Adolescents (Ages 6-17 Years) With Attention Deficit Hyperactivity Disorder
NCT03006367 is registered in ClinicalTrials.gov with Aevi Genomic Medicine, LLC, a Cerecor company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Single Ascending Dose, Pharmacokinetic and Tolerability Study of NFC-1 in Children and Adolescents (Ages 6-17 Years) With Attention Deficit Hyperactivity Disorder
- Lead sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 7, 2017
- Completion date
- March 6, 2017
- Enrollment
- 32 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.